Gerald J. Dal Pan

Real-World Evidence — What Is It and What Can It Tell Us?

Rachel E. Sherman, Steven A. Anderson, Gerald J. Dal Pan et al. · New England Journal of Medicine · 2016 · 2.1K citations

Law, Health Informatics, Health Policy +17

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System

Takashi Kishimoto, Karthik Viswanathan, Tanmoy Ganguly et al. · New England Journal of Medicine · 2008 · 616 citations · Full text

Medicine, Immunology, Pharmacology +12

Graphical Depiction of Longitudinal Study Designs in Health Care Databases

Sebastian Schneeweiß, Jeremy A. Rassen, Jeffrey S. Brown et al. · Annals of Internal Medicine · 2019 · 268 citations · Full text

Computing, Pharmacoeconomics, Visualization +17

The FDA's sentinel initiative—A comprehensive approach to medical product surveillance

Robert Ball, Melissa A. Robb, SA Anderson et al. · Clinical Pharmacology & Therapeutics · 2015 · 251 citations

Pharmacy, Health Policy, Health Services Administration +16

The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma

Badrul A. Chowdhury, Gerald J. Dal Pan · New England Journal of Medicine · 2010 · 249 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13